Therefore, cladribine and alemtuzumab significantly compromise immune defenses against infection.
Some studies have shown that omitting a second dose of
alemtuzumab may still lead to significant disease control50. Nevertheless, more
data are necessary before we can affirm this omission will
not compromise the long-term efficacy of the therapy.